The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020;383:8 de octubre. [Ref.ID 103732]

Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Rajagopalan B, On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias. A scientific statement from the American Heart Association. Circulation 2020;142:16 de septiembre. [Ref.ID 103712]

Zaroff JG, Cheetham TC, Palmetto N, Almers L, Quesenberry C, Schneider J, Gatto N, Corley DA. Association of azithromycin use with cardiovascular mortality. JAMA Network Open 2020;3:17 de junio. [Ref.ID 103669]

Anónimo. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration 2020:1. [Ref.ID 103663]

Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, Moslehi JJ, Roden DM, Funck-Brentano C, Salem J-E. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation 2020;142:22 de mayo. [Ref.ID 103660]

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]

Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]

Borraz M, Ferrer S. Historia de un escándalo: una empresa sospechosa y el estudio que sacudió a la prestigiosa revista 'The Lancet' . eldiario.es 2020:6 de junio. [Ref.ID 103642]

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:29 de abril. [Ref.ID 103630]

Bessière F, Roccia H, Delinière A, Chevalier P, Argaud L, Cour M. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiology 2020:1 de mayo. [Ref.ID 103614]

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiology 2020:1 de mayo. [Ref.ID 103613]

Sakoulas G, El Sahly H, Ellison III RT. Chloroquine and hydroxychloroquine: old drugs in a new COVID-19 world. Journal Watch 2020:. [Ref.ID 103608]

Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020:24 de abril. [Ref.ID 103600]

Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:8 de abril. [Ref.ID 103595]

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]

Girard TD , Exline MC , Carson SS , Hough CL , Rock P , Gong MN , Douglas IS , Malhotra A , Owens RL , Feinstein DJ , Khan B , Pisani MA , Hyzy RC , Schmidt GA , Schweickert WD , Hite RD , Bowton DL , Masica AL , Thompson JL , Chandrasekhar R , Pun BT , Strength C , Boehm LM , Jackson JC , Pandharipande PP , Brummel NE , Hughes CG , Patel MB , Stollings JL , Bernard GR , Dittus RS , Ely EW , for the MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in vritical illness. N Engl J Med 2018;379:22 de octubre. [Ref.ID 102838]